These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 34481195)

  • 21. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Near-infrared light switching nitric oxide nanoemitter for triple-combination therapy of multidrug resistant cancer.
    Wei G; Yang G; Wei B; Wang Y; Zhou S
    Acta Biomater; 2019 Dec; 100():365-377. PubMed ID: 31586724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons.
    Majidinia M; Mirza-Aghazadeh-Attari M; Rahimi M; Mihanfar A; Karimian A; Safa A; Yousefi B
    IUBMB Life; 2020 May; 72(5):855-871. PubMed ID: 31913572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of ABC transporters in cancer chemotherapy.
    Sun YL; Patel A; Kumar P; Chen ZS
    Chin J Cancer; 2012 Feb; 31(2):51-7. PubMed ID: 22257384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innovative nanochemotherapy for overcoming cancer multidrug resistance.
    Tan H; Zhang M; Wang Y; Timashev P; Zhang Y; Zhang S; Liang XJ; Li F
    Nanotechnology; 2021 Nov; 33(5):. PubMed ID: 34700307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming cellular multidrug resistance using classical nanomedicine formulations.
    Kunjachan S; Błauż A; Möckel D; Theek B; Kiessling F; Etrych T; Ulbrich K; van Bloois L; Storm G; Bartosz G; Rychlik B; Lammers T
    Eur J Pharm Sci; 2012 Mar; 45(4):421-8. PubMed ID: 21907796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Approaches of Dual-targeted Nanomedicines for Tumor Multidrug Resistance.
    Han W; Shen Z; Zou J; Ye Q; Ge C; Zhao Y; Wang T; Chen Y
    Curr Drug Deliv; 2024; 21(2):155-167. PubMed ID: 37143266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidrug resistance: Physiological principles and nanomedical solutions.
    Kunjachan S; Rychlik B; Storm G; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1852-1865. PubMed ID: 24120954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using nanotechnology to progress the utilization of marine natural products in combating multidrug resistance in cancer: A prospective strategy.
    Bhusare N; Gade A; Kumar MS
    J Biochem Mol Toxicol; 2024 Jun; 38(6):e23732. PubMed ID: 38769657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models.
    Petrikaite V; D'Avanzo N; Celia C; Fresta M
    Drug Resist Updat; 2023 May; 68():100956. PubMed ID: 36958083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer.
    Yuan Y; Cai T; Xia X; Zhang R; Chiba P; Cai Y
    Drug Deliv; 2016 Nov; 23(9):3350-3357. PubMed ID: 27098896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relevance of multidrug resistance in the age of targeted therapy.
    Türk D; Szakács G
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.
    Li W; Zhang H; Assaraf YG; Zhao K; Xu X; Xie J; Yang DH; Chen ZS
    Drug Resist Updat; 2016 Jul; 27():14-29. PubMed ID: 27449595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
    Pérez-Tomás R
    Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Progression on Multifunctional Nanoparticles Interfering with Cell Membrane Transporters-associated Drug Resistance].
    Jiang WX; Ren JL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Aug; 43(4):620-627. PubMed ID: 34494535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversion of multidrug resistance by a pH-responsive cyclodextrin-derived nanomedicine in drug resistant cancer cells.
    Shi Q; Zhang L; Liu M; Zhang X; Zhang X; Xu X; Chen S; Li X; Zhang J
    Biomaterials; 2015 Oct; 67():169-82. PubMed ID: 26218743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanomedicine solutions to intricate physiological-pathological barriers and molecular mechanisms of tumor multidrug resistance.
    Li Y; Xu X
    J Control Release; 2020 Jul; 323():483-501. PubMed ID: 32387548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.
    Yadav P; Ambudkar SV; Rajendra Prasad N
    J Nanobiotechnology; 2022 Sep; 20(1):423. PubMed ID: 36153528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanomedicine to overcome cancer multidrug resistance.
    Yang X; Yi C; Luo N; Gong C
    Curr Drug Metab; 2014; 15(6):632-49. PubMed ID: 25255871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.